Artelo Biosciences, Inc. filed an 8-K on October 9, 2026, stating it has no information regarding the duration of the temporary stay on Nasdaq's new listing compliance rule or whether the rule will be reinstated in its current form. The filing highlights the regulatory uncertainty surrounding the $5,000,000 Market Value of Listed Securities (MVLS) requirement that currently affects approximately 180 Nasdaq-listed companies, including Artelo.
The Securities and Exchange Commission approved Nasdaq's new rule on July 22, 2026. This rule mandates that listed companies maintain an MVLS of at least $5,000,000. Companies falling below this threshold face potential delisting proceedings unless they can demonstrate a plan to regain compliance within a specified period. Artelo Biosciences was among the companies initially identified as having an MVLS below the new threshold when the rule was first approved.
On July 29, 2026, a temporary stay of the $5M MVLS Rule was announced. Following this stay, Nasdaq published a notice for a proposed rule change on October 5, 2026. The proposal seeks to modify the operative date of the rule to coincide with the termination of the temporary stay. Comments on this proposed change are due by October 29, 2026.
In its filing, Artelo stated that it intends to monitor developments related to the rule. If the rule takes effect in a form that applies to the company, management expects to consider steps available to regain or maintain compliance. The company listed potential actions that could be taken, which depend on the final form of the rule and prevailing circumstances.
These potential steps include raising capital through its existing at-the-market equity offering program or other equity or equity-linked financings. Other options mentioned include actions regarding outstanding warrants or other securities, continued advancement of development programs, management of operating expenses, and other corporate actions. Artelo explicitly stated it has not committed to any particular course of action and is not soliciting proposals for any transaction.
The company noted that there can be no assurance that it will take any particular action or that any specific transaction or strategy will be completed. Additionally, there is no assurance that such actions would result in achieving or maintaining compliance with the $5M MVLS Rule. Artelo indicated that it will not provide additional updates until it decides that such information is suitable or mandatory for release.
The filing was signed by Gregory D. Gorgas, Chief Executive Officer and President of Artelo Biosciences. The company is incorporated in Nevada and has its principal executive offices in Solana Beach, California. Its common stock trades on The Nasdaq Stock Market LLC under the ticker symbol ARTL.